ActHIB
Sponsors
GlaxoSmithKline, Nuron Biotech Inc.
Conditions
Acellular PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis BInfectious DiseaseNeisseria MeningitidisPoliomyelitisTetanus
Phase 2
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
CompletedNCT00129129
Start: 2004-08-01End: 2006-03-29Updated: 2018-08-24
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
NCT01732198
Start: 2013-03-31End: 2014-04-30Target: 220Updated: 2013-09-23
Phase 3
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
CompletedNCT00289783
Start: 2006-02-22End: 2008-02-26Updated: 2018-08-24
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
CompletedNCT00345579
Start: 2006-09-30End: 2008-03-31Updated: 2016-12-16
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
CompletedNCT02096263
Start: 2014-04-16End: 2015-11-13Updated: 2019-11-27